期刊文献+

Systematic review and meta-analysis of efficacy of Gexia Zhuyu Decoction in the treatment of nonalcoholic fatty liver disease

下载PDF
导出
摘要 Objective:To evaluate the efficacy of Gexia Zhuyu Decoction in the treatment of nonalcoholic fatty liver disease(NAFLD).Methods:Four Chinese databases(CNKI,CMB,Wanfang,VIP)and four English databases(PubMed,Embase,Cochrane Library,Medline)were searched to screen randomized controlled trials(RCTs)of Gexia Zhuyu Decoction in the treatment of NAFLD.The enrollment of RCTs is from the starting date of database establishment till November 2,2022.and clinical registration tests and grey literatures were also searched.RCTs screening and relevant data exreacting were based on preset criteria.RevMan5.4.1 software was used for risk of bias assessment and Meta analysis of the included studies.Results:Eleven RCTs were included finally having 963 patients with NAFLD,including 499 in experimental group and 494 in control group.Meta-analysis results showed that GexiaZhuyu Decoction alone or combining with other medications for the treatment of NFALD was superior to that in control group in terms of total effective rate[RR=1.23,95%CI[1.16,1.31],Z=6.58(P<0.05)].Improve liver function index significantly:ALT[subgroup①WMD=-14.93,95%CI[-18.66,-9.42],Z=7.84(P<0.01);subgroup②WMD=-3.97,95%CI[-8.01,0.07],AST[subgroup①WMD=-13.25,95%CI[-18.10,-8.41],Z=5.36(P<0.05);subgroup②WMD=-2.70,95%CI[-6.94,1.54],Z=1.25(P>0.05)];GGT[WMD=-9.30,95%CI[-15.78,-2.81],Z=2.81(P<0.05)].Moreover,patients with therapy obviously decreased hepatic fibrosis index:桇-C[SMD=-1.15,95CI%[-1.48,-0.81],Z=6.77(P<0.05)],LN[SMD=-1.49,95CI%[-2.23,-0.75],Z=3.97(P<0.05)].Effectively reduce the level of LDL-C[WMD=-0.30,95CI%[-0.54,-0.06],Z=2.48(P<0.05)]and improve the rate of ultrasound renormalization[RR=1.94,95%CI[1.45,2.60],Z=4.48(P<0.05)].However,existing data cannot prove that the effect of reducing TC,TG and BMI in the treatment group is better than that in the control group:TC[WMD=-0.88,95CI%[-1.88,0.11],Z=1.74(P>0.05)],TG[WMD=-0.50,95CI%[-1.05,0.06],Z=1.76(P>0.05)],BMI[WMD=-1.61,95CI%[-4.77,1.54],Z=1.00(P>0.05)].Descriptive analysis results showed that the levels of LDL,HA and PCIII were significantly reduced in the treatment group,and the differences were statistically significant(P<0.05).In addition,no adverse drug reactions related to Gexia Zhuyu Decoction have been reported.Conclusion:Gexia Zhuyu Decoction can significantly improve the liver function,liver fibrosis,and hepatic steatosis in NAFLD patients,thereby improving the clinical efficacy.
出处 《Journal of Hainan Medical University》 CAS 2023年第10期50-60,共11页 海南医学院学报(英文版)
基金 National Natural Science Foundation of China(No.81603418) Outstanding Young Talents Project of Heilongjiang Province(No.2020YQ05)。
  • 相关文献

参考文献8

二级参考文献79

  • 1中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中国肝脏病杂志(电子版),2010,2(4):43-48. 被引量:468
  • 2关丽明,方亮,胡军,郭文.多烯磷脂酰胆碱(易善复)联合辛伐他汀治疗酒精性肝病的临床观察[J].国际医药卫生导报,2006,12(22):69-71. 被引量:12
  • 3中华医学会肝脏病学会脂肪肝和酒精性肝病学组.非酒精性脂肪肝病诊疗指南.中华肝病学杂志,2006,:161-161.
  • 4胡建华,李晓东,李秀惠,聂广,杨大国.中医药治疗肝纤维化无创性疗效评定标准的探讨[J].中西医结合肝病杂志,2007,17(4):208-210. 被引量:12
  • 5Clouston AD, Powell EE. Nonalcoholic fatty liver disease: is all the fat bad? Intern Med ] 2004; 34: 187-191.
  • 6Marignani M, Angeletti S. Nonalcoholic fatty liver disease. N Engl J Med 2002; 347: 768-769; author re- ply 768-769.
  • 7Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Mar- chesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepa- to12010; 53:372-384.
  • 8陈可冀,廖家桢,肖镇祥.心脑血管次病研究.上海:上海科学技术出版社,1988:311-313.
  • 9中华人民共和国卫生部中药新药临床研究指导原则(第二辑).2002:67-89.
  • 10Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A, What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? ] Gastroenterol Hepato12007; 22:794-800.

共引文献123

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部